iFLYTEK Medical today announced a major breakthrough: the world's first Type 1 diabetes specialized large model, developed based on core achievements from the national "four major chronic diseases" major project, has been officially unveiled. This marks a significant scientific achievement transitioning from the laboratory to clinical application, and represents the first successful national-level major scientific research project outcome conversion in chronic disease prevention and control in Anhui Province.
This project focuses on key pain points in the Type 1 diabetes diagnosis and treatment process. By integrating multimodal data and extensive clinical experience, and leveraging the powerful technological foundation of iFLYTEK's StarFire Medical large model X1, it has built a digitalized prevention and control system covering the entire process from screening, typing, treatment to management.
According to iFLYTEK, the specialized large model was jointly developed by iFLYTEK Medical and multiple research institutions, with Professor Jianping Weng, Chair Professor of University of Science and Technology of China and President of Anhui Medical University, serving as the chief scientist. The model has built a three-pronged intelligent support system aimed at comprehensively improving the diagnosis and treatment level of Type 1 diabetes:
- Authoritative Knowledge Center: Systematically integrates clinical pathways from 65 specialized scenarios, 135 authoritative diagnostic and treatment guidelines, and up to 20 million real patient case data, forming a leading domestic professional knowledge system for Type 1 diabetes.
- Dynamic Sensing Network: Leveraging AIoT technology, the system can monitor 14-dimensional metabolic parameters of patients in real time, with an abnormal blood glucose capture sensitivity as high as 99.2%, a 40% improvement over traditional monitoring methods.
- Decision Support Engine: This engine relies on the advanced capabilities of iFLYTEK's StarFire Medical large model X1, including AGP graph analysis, deep medical knowledge, medical deep reasoning, precise blood glucose prediction, and multimodal interaction. It can generate personalized treatment plans for patients in eight dimensions, including diet, exercise, and insulin adjustment, marking the entry of Type 1 diabetes diagnosis and treatment into the era of "personalized treatment for each individual".
Even more noteworthy is iFLYTEK Medical's claim that this Type 1 diabetes specialized large model has surpassed the currently highly-regarded general large models GPT-4 and DeepSeek-R1 in tests across 65 core application scenarios, including prevention, diagnosis, treatment, follow-up, diet and exercise, and pregnancy. This news undoubtedly brings new hope to Type 1 diabetes patients and signifies the increasingly important role of artificial intelligence in chronic disease management.
